Exploring New and Emerging ATTs to Inform Patient Selection and Increase Optimal Care in a Timely Manner

This activity is part of a series


Eric G. Tangalos, MD, FACP, AGSF, CMD
Professor of Medicine
Division of Primary Care Internal Medicine, Geriatrics and Palliative Care
Mayo Clinic
Rochester, MN
Eric G. Tangalos, MD, FACP, AGSF, CMD

Dr. Eric Tangalos is Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He served as Chair of Primary Care Internal Medicine from 1997 to 2006. Dr. Tangalos received his undergraduate training from the University of Michigan, is a graduate of the Loyola University Stritch School of Medicine in Chicago, and was a resident and fellow in Internal Medicine at Mayo.

He is a past president of AMDA, The Society for Post-Acute and Long-Term Care Medicine, and is a fellow and past governor of the American College of Physicians. He is a past director of the American Geriatrics Society and serves on their Foundation for Health in Aging. Dr. Tangalos served 8 years on the national board of the Alzheimer’s Association and was a member of their executive committee. He also served as Chair of the Omnicare P&T Committee for 20 years.

Dr. Tangalos was Medical Director at the Samaritan Bethany nursing home from 1981 until his retirement from Mayo in 2019.  His certification as a medical director is current and will be approved again by the American Board of Post-Acute and Long-Term Care Medicine (ABPLM) in June 2022.  He is currently recredentialed by Mayo for continuing service both to the Rochester campus and the Health Care System in Minnesota.  Over the past 3 years he has worked face-to-face with patients in Austin and has provided in-basket coverage to Austin, Albert Lea, Faribault, and Owatonna.

Dr. Tangalos has been an investigator with the Mayo Clinic Alzheimer’s Disease Research Center since 1987 and is currently active with the Alzheimer’s Association as course director for a Project ECHO seminar series. Additionally, Dr. Tangalos continues to review NIH SBIR/STTR grant applications while working as a founding member of the American Telemedicine Association.

Nicolas Villain, MD, PhD
Associate Professor of Neurology
Sorbonne University
Institute of Memory and Alzheimer’s Disease
Department of Neurology
Pitié-Salpêtrière Hospital
Assistance Publique – Hôpitaux de Paris
Paris, France
Nicolas Villain, MD, PhD

Nicolas Villain, MD, PhD, is a tenured Associate Professor of Neurology at Sorbonne University, Paris, France and a cognitive and behavioral neurologist at the Institute of Memory and Alzheimer’s Disease, Department of Neurology, Pitié-Salpêtrière Hospital, Paris. He trained as an MD and a clinical fellow in Paris in Prof. Bruno Dubois’ group and carried out his PhD with Dr. Gaël Chételat in Caen, France, where he worked on multimodal neuroimaging and disconnection mechanisms in Alzheimer’s disease. He currently leads projects on brain network vulnerability using multimodal neuroimaging and on fluid biomarkers of Alzheimer’s disease in Prof. Kaj Blennow’s new group at the Paris Brain Institute.

Statement of Need

Each day matters when it comes to slowing the progression of Alzheimer’s disease (AD), so it is imperative that health care professionals (HCPs) in this field are able to provide optimal care for patients with AD in a timely manner while applying the latest clinical trial data to practice, including the varied safety and efficacy data on new and emerging amyloid-targeting therapies (ATTs). ATTs have been shown to be promising in delaying disease progression in individuals with mild cognitive impairment or early dementia due to AD. To realize the full potential of ATTs, HCPs need education on clinical data of ATT agents in order to appropriately translate that information to improve diagnosis and management of AD.

In this CME Outfitters Snack, expert faculty will review data presented at the Alzheimer’s Association International Conference (AAIC) and will focus on established, new, and emerging ATTs as well as a case-based discussion on clinical impacts and applications to provide point-of-care tactics that will have a positive impact on patient outcomes.

Learning Objective

Evaluate clinical practice implications of clinical trial data for established and emerging ATTs.

Financial Support

This activity is supported by an educational grant from Lilly.

Target Audience

Dementia specialists, neurologists, psychiatrists, neurology and psychiatry nurse practitioners (NPs), physician associates (PAs), and other clinicians caring for patients with AD in the United States and globally (with the exception of UK-based clinicians)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.75

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.75

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hour. Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

PAs (AAPA) 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Tangalos reports the following financial relationships:

Advisory Board: Acadia Pharmaceuticals Inc.; Biogen; and Eisai Inc.

Consultant: Cyclo Therapeutics, Inc. (DSMB); Genentech, Inc.; Prothena (DSMB); and Roche

Stock Shareholder (ownership interest): AbbVie Inc.; Johnson & Johnson; and Pfizer Inc.

Dr. Villain reports the following financial relationships:

Grants: Travel grant from GE Healthcare SAS; Merz-Pharma; and UCB Pharma GmbH

Other financial or material support: Unpaid local principal investigator or sub-investigator for Alector, Inc.; Biogen; Eisai Inc.; Eli Lilly and Company; Janssen Global Services, LLC/Johnson & Johnson; Novo Nordisk A/S; Roche; and UCB Pharma. Unpaid national coordinator for AB Science and ADvantage Therapeutics GmbH.

Unpaid lecturer in symposia organized by Eisai Inc. and the Servier Foundation.

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

  • Joshua Caballero, PharmD, BCPP, FCCP (peer reviewer)
  • Susan Perry (planning committee)
  • Kellie Busby, PharmD, BCPP (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Exploring New and Emerging ATTs to Inform Patient Selection and Increase Optimal Care in a Timely Manner
Event Date: 08/09/2023